Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2011-08-29
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well giving rituximab and dexamethasone
together works in treating patients with low-grade non-Hodgkin lymphoma (NHL). Monoclonal
antibodies, such as rituximab, can block cancer growth in different ways. Some block the
ability of cancer cells to grow and spread. Others find cancer cells and help kill them or
carry cancer-killing substances to them. Drugs used in chemotherapy, such as dexamethasone,
work in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving rituximab together with dexamethasone may kill more
cancer cells